WASHINGTON – Combination products have proved nettlesome for the FDA. Despite that recent legislation seemed to tackle several major headaches, two speakers at the Food and Drug Law Institute annual meeting said questions persist, including the issue of how a combo product's primary mode of action will be determined by the FDA.